Newsletter
Language
Language:
 
News
Archival Issues
Volume 18, 2016
Volume 17, 2015
Volume 16, 2014
Volume 15, 2013
Volume 14, 2012
Volume 13, 2011
Volume 12, 2010
Volume 11, 2009
Volume 10, 2008
Volume 9, 2007
Volume 8, 2006
Volume 7, 2005
Volume 6, 2004
Volume 5, 2003
Volume 4, 2002
Volume 3, 2001
Volume 2, 2000
Volume 1, 1999
Search
 » 
Journal Abstract
 
Treatment of Spasticity with Botulinum Toxin
Yasuhiko Baba, M.D., Michael D Osborne, M.D., Zbigniew K. Wszolek, M.D., Andrzej Kwolek, Mariusz Dru┼╝bicki Ph. D.
Ortop Traumatol Rehabil 2004; 6(5):665-672
ICID: 15750
Article type: Review article
IC™ Value: 4.67
Abstract provided by Publisher
 
Spasticity is a complex disorder characterized by a velocity-dependent increase in muscle tone associated with exaggerated deep tendon reflexes. It can be caused by numerous diffuse or focal cerebral and spinal pathologic conditions. Spasticity indicates upper motor neuron dysfunction and if severe, can lead to considerable motion restriction and eventually to more serious disability.
The therapeutic interventions available to treat spasticity are often of limited benefit. In the last decade, many open-label and several double-blind, placebo-controlled, studies have demonstrated the effectiveness of intramuscular botulinum toxin (BTX) injections for the management of spasticity caused by multiple sclerosis, brain / spinal cord injury, cerebral palsy, and stroke. BTX can also be beneficial in the treatment of spasticity, or a mixture of spasticity and rigidity, in many neurodegenerative conditions; including Parkinson disease, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia and parkinsonism linked to chromosome 17, and in various sporadic and familial spinocerebellar ataxia syndromes.
Currently, two BTX serotypes, which are serologically different but share a common subunit structure, are commercially available: type A (Botox®, manufactured by Allergan, Inc, Irvine, California, USA; and Dysport®, distributed by Beaufour-Ipsen Pharmaceuticals, Paris, France); and type B (manufactured by Elan Corporation, Dublin, Ireland, and available in the United States as MyoBloc® and in Europe as NeuroBloc®). BTX primarily affects the neuromuscular junction by inhibiting acetylcholine release. Dosages vary considerably depending on the particular preparation used, the muscle injected, the severity of the condition, and the duration of treatment.

ICID 15750
PMID 17618218 - click here to show this article in PubMed
 
FULL TEXT 1357 KB


Related articles
  • in IndexCopernicus™
         Stroke [123 related records]
         Cerebral Palsy [164 related records]
         spinal cord injury [15 related records]
         brain injury [10 related records]
         Multiple Sclerosis [210 related records]
         upper motor neuron [2 related records]

  • Related articlesin PubMed database
  • in PubMed database [ related records]


  •  

    Copyright © Ortopedia Traumatologia Rehabilitacja  2017
    Page created by Index Copernicus Ltd. All Rights reserved.